Cheng Z, Chai Y, Zhou Z, Zhang Y
Front Pediatr. 2025; 13:1450634.
PMID: 39944318
PMC: 11816113.
DOI: 10.3389/fped.2025.1450634.
Jin X, Tong W, Sun L, Lu S, Xu T, Sun P
Front Nutr. 2025; 11:1514320.
PMID: 39758322
PMC: 11695336.
DOI: 10.3389/fnut.2024.1514320.
Hay-Smith E, Starzec-Proserpio M, Moller B, Aldabe D, Cacciari L, Pitangui A
Cochrane Database Syst Rev. 2024; 12:CD009508.
PMID: 39704322
PMC: 11660230.
DOI: 10.1002/14651858.CD009508.pub2.
Kim S, Park S, Pak S, Lee Y, Cho S
World J Urol. 2024; 43(1):22.
PMID: 39656264
DOI: 10.1007/s00345-024-05347-w.
Krhut J, Kobbero H, Kanaan R, Fode M, Poulsen M, Zvara P
Nat Rev Urol. 2024; .
PMID: 39653756
DOI: 10.1038/s41585-024-00967-8.
Sacral and Implantable Tibial Neuromodulation for the Management of Overactive Bladder: A Systematic Review and Meta-analysis.
Amundsen C, Sutherland S, Kielb S, Dmochowski R
Adv Ther. 2024; 42(1):10-35.
PMID: 39476308
PMC: 11782405.
DOI: 10.1007/s12325-024-03019-0.
Effect of standard urotherapy to children with overactive bladder on quality of life.
Dai R, Chen Y, Fan S, Xia J, Jiang S, Peng Y
World J Urol. 2024; 42(1):593.
PMID: 39455444
DOI: 10.1007/s00345-024-05310-9.
Safety and effectiveness of mirabegron for children and adolescents with refractory idiopathic overactive bladder for improving urinary symptoms: a systematic review.
Franco-Buenaventura D, Garcia-Perdomo H
Cent European J Urol. 2024; 77(2):206-212.
PMID: 39345308
PMC: 11428357.
DOI: 10.5173/ceju.2023.237.
Botulinum Neurotoxin Type A in paediatric non-neurogenic therapy resistant overactive bladder: a cohort study.
Hougaard N, Breinbjerg A, Kamperis K, Skott M
Int Urol Nephrol. 2024; 57(2):341-346.
PMID: 39327408
PMC: 11772385.
DOI: 10.1007/s11255-024-04217-z.
Efficacy and safety of intradetrusor abobotulinumtoxinA and incobotulinumtoxinA in women with overactive bladder and the value of local anesthesia: a randomized clinical study.
Kavcic N, Avsenak A, Zmazek J, Serdinsek T, But I
Wien Klin Wochenschr. 2024; .
PMID: 39179906
DOI: 10.1007/s00508-024-02412-7.
Effectiveness of non-pharmacological interventions delivered at home for urinary and faecal incontinence with homebound older people: systematic review of randomised controlled trials.
Buck J, Fromings Hill J, Collins R, Booth J, Fleming J
Age Ageing. 2024; 53(6).
PMID: 38941119
PMC: 11212545.
DOI: 10.1093/ageing/afae126.
Assessment of the Therapeutic Effectiveness of Glutathione-Enhanced Mesenchymal Stem Cells in Rat Models of Chronic Bladder Ischemia-Induced Overactive Bladder and Detrusor Underactivity.
Shin J, Yu H, Kwon H, Yun H, Ryu C, Shin D
Int J Stem Cells. 2024; 18(1):72-86.
PMID: 38631809
PMC: 11867900.
DOI: 10.15283/ijsc23147.
Topical estrogen therapy ameliorates bladder estrogen receptor β expression in female patients with overactive bladder.
Ren C, Qiang Z
Am J Transl Res. 2024; 15(12):6849-6857.
PMID: 38186992
PMC: 10767533.
Association between weight-adjusted-waist index and urge urinary incontinence: a cross-sectional study from NHANES 2013 to 2018.
Sun H, Huang J, Tang H, Wei B
Sci Rep. 2024; 14(1):478.
PMID: 38177657
PMC: 10767076.
DOI: 10.1038/s41598-024-51216-2.
Urinary incontinence associates with poor work ability in middle-aged women: A Northern Finland Birth cohort 1966 study.
Salo H, Makela-Kaikkonen J, Sova H, Piltonen T, Laru J, Ala-Mursula L
Acta Obstet Gynecol Scand. 2023; 103(3):572-579.
PMID: 38037668
PMC: 10867356.
DOI: 10.1111/aogs.14743.
Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B
Medicine (Baltimore). 2023; 102(S1):e32377.
PMID: 37499088
PMC: 10374192.
DOI: 10.1097/MD.0000000000032377.
Efficacy and safety of vaginal electrical stimulation as an alternative or adjunct treatment for overactive bladder syndrome in women: a meta-analysis of randomized controlled trials.
Huang J, Fan Y, Wang D, Deng Q, Zou X, Yu J
Int Urogynecol J. 2023; 34(10):2345-2357.
PMID: 37368020
DOI: 10.1007/s00192-023-05546-w.
Translation and validation of Incontinence Impact Questionnaire Short Form in the Urdu language.
Tassawer Q, Noor R, Ikram M, Bashir M
Int Urogynecol J. 2023; 34(9):2285-2292.
PMID: 37115206
DOI: 10.1007/s00192-023-05554-w.
Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder-Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes.
Ou Y, Kao Y, Ho Y, Wu K, Kuo H
Toxins (Basel). 2023; 15(2).
PMID: 36828410
PMC: 9967532.
DOI: 10.3390/toxins15020095.
Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder.
Shaw C, Gibson W
Ther Clin Risk Manag. 2023; 19:27-33.
PMID: 36647532
PMC: 9840370.
DOI: 10.2147/TCRM.S269318.